Literature DB >> 26403391

PHYSIOPATHOLOGY OF OSTEOPOROSIS: FROM RISK FACTORS ANALYSIS TO TREATMENT.

A Del Puente2, A Esposito1, A Del Puente2, L Costa1, F Caso1, R Scarpa1.   

Abstract

Osteoporosis represents a relevant health issue, being the first cause of bone fractures in the elderly with subsequent implications in terms of survival and social costs. The improved knowledge about the physiopathology of this disease has led to a new definition of Osteoporosis, which shifts the attention from the “"decrease in bone mass"” to several elements related to what has globally been defined as bone quality. In fact, it has been shown that clinical risk factors affecting bone homeostasis coincide with osteoporosis risk factors. The evaluation of such clinical risk factors is an important element in the assessment of the global fracture risk. The availability of instruments for the assessment of the global fracture risk also suggests a change in the clinical perspective and raises new questions as yet unanswered.

Entities:  

Mesh:

Year:  2015        PMID: 26403391

Source DB:  PubMed          Journal:  J Biol Regul Homeost Agents        ISSN: 0393-974X            Impact factor:   1.711


  6 in total

1.  A Matrine Derivative M54 Suppresses Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss by Targeting Ribosomal Protein S5.

Authors:  Zhi Xin; Cui Jin; Liu Chao; Zhang Zheng; Cao Liehu; Pan Panpan; Weng Weizong; Zhai Xiao; Zhao Qingjie; Hu Honggang; Qin Longjuan; Chen Xiao; Su Jiacan
Journal:  Front Pharmacol       Date:  2018-01-30       Impact factor: 5.810

2.  Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis.

Authors:  Xiao Chen; Xin Zhi; Panpan Pan; Jin Cui; Liehu Cao; Weizong Weng; Qirong Zhou; Lin Wang; Xiao Zhai; Qingiie Zhao; Honggang Hu; Biaotong Huang; Jiacan Su
Journal:  FASEB J       Date:  2017-07-24       Impact factor: 5.191

3.  Vindoline Inhibits RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss in Mice.

Authors:  Yunfei Zhan; Jiamin Liang; Kun Tian; Zhigang Che; Ziyi Wang; Xue Yang; Yuangang Su; Xixi Lin; Fangming Song; Jinmin Zhao; Jiake Xu; Qian Liu; Bo Zhou
Journal:  Front Pharmacol       Date:  2020-01-22       Impact factor: 5.810

Review 4.  The therapeutic potential of mesenchymal stem cells in treating osteoporosis.

Authors:  Tianning Chen; Tieyi Yang; Weiwei Zhang; Jin Shao
Journal:  Biol Res       Date:  2021-12-20       Impact factor: 5.612

5.  Matrine derivate MASM uncovers a novel function for ribosomal protein S5 in osteoclastogenesis and postmenopausal osteoporosis.

Authors:  Xiao Chen; Xin Zhi; Liehu Cao; Weizong Weng; Panpan Pan; Honggang Hu; Chao Liu; Qingjie Zhao; Qirong Zhou; Jin Cui; Jiacan Su
Journal:  Cell Death Dis       Date:  2017-09-07       Impact factor: 8.469

6.  Artesunate inhibits osteoclastogenesis through the miR-503/RANK axis.

Authors:  Ming-Zhi Huang; Yong Zhuang; Xu Ning; Hao Zhang; Zhi-Min Shen; Xian-Wen Shang
Journal:  Biosci Rep       Date:  2020-07-31       Impact factor: 3.840

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.